The Biden administration is contemplating creating a research agency to help fund breakthroughs that aren’t economically viable for big health and pharmaceutical companies. Meet HARPA.
Insulin, a hormone that turns sugar into energy, is notoriously expensive. Diabetics, which lack the hormone, can pay as much as $700 for five injection pens. But what if we could invent a more efficient supply chain that brought down the cost? Or better yet, what if we could create a market-ready technology that could reverse diabetes?